Open Nav

Dr. Reddy's Laboratories

  • Wenn Sun, Dr. Reddy's Laboratories

Licensing, Partnering for Development & Commercialization

  • Date:Wednesday, October 17
  • Time:11:00 AM - 11:15 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Dr. Reddy’s Laboratories is an integrated pharmaceutical company, headquartered in Hyderabad, India, committed to providing affordable and innovative medicines for healthier lives. Through our three businesses— Pharmaceutical Services and Active Ingredients; Global Generics; and Proprietary Products— Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe.
  • Company Website:www.drreddys.com
  • Company HQ City:Hyderabad
  • Company HQ Country:India
  • Market Cap:~ 6 Bn. USD
  • Ticker:RDY (NYSE, USA), DRREDDY (NSE, INDIA)
  • Exchange:NYSE-USA, NSE-INDIA
  • CEO/Top Company Official:G.V. Prasad
  • Year Founded:1984
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :E7777 (denileukin diftitox)
  • Development Phase of Primary Product:Multiple Products in Market
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:E7777 (denileukin diftitox, previously ONTAK®), consists of full length amino acid sequences of IL2 and fragments of diphtheria toxin. E7777 binds to cells expressing the high affinity IL2R resulting in internalization and release of cytotoxic diphtheria fragments, leading to cell death. E7777 is currently in registration phase for CTCL with an anticipated BLA filing in mid-2019. DD targets the high affinity IL-2Ra and has been shown to be effective in depleting Tregs in both animal models and in humans. E7777 has been extensively studied as a targeted therapy in CTCL/PTCL patients and in other tumor types as a Treg depletion agent. Significant data suggests that this would represent a low risk, highly promising approach to modulate Tregs to further potentiate the efficacy of other I/O treatment mechanisms such as adoptive cell therapies, CPIs, CAR-Ts, etc. DRL is seeking partners to further develop denileukin diftitox in immuno-oncology.
Speakers
Wenn Sun
Dr. Reddy's Laboratories
Back